News | August 20, 2014

Boston Scientific, Asahi Intecc Announce Joint Development, Manufacturing Programs

August 20, 2014 — Boston Scientific Corp. and Asahi Intecc have formalized plans to develop a new, differentiated fractional flow reserve (FFR) wire. The joint project focuses on creating a device intended to improve handling compared to existing FFR wires.

The FFR market is an emerging field in interventional cardiology that exceeds $250 million worldwide and is experiencing a double-digit growth rate. FFR-guided percutaneous coronary intervention (PCI) is cost-effective and also reduces one-year major adverse cardiac events (MACE) rates. The jointly developed FFR wire will be designed for use with the Boston Scientific Polaris multimodality imaging system.

The companies have also agreed to collaborate on key enhancements to the Boston Scientific RotaWire atherectomy guidewire. Asahi Intecc will provide components for the new RotaWire, which is designed by Boston Scientific to provide improved control and handling. The RotaWire is a unique 0.009-inch wire that is used within the Rotablator rotational atherectomy system to treat calcified lesions in coronary arteries.

The introduction of the components manufactured by Asahi Intecc to advance the RotaWire atherectomy guidewire is further evidence of the Boston Scientific commitment to improving products used in the treatment of complex coronary disease.

"We expect our collaboration with Asahi Intecc to help improve care for patients with coronary artery disease and strengthen our interventional cardiology portfolio," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "The Asahi Intecc expertise in guidewire technology is unparalleled. By leveraging the strengths of our technologies, we have the opportunity to create truly differentiated products."

"Boston Scientific has advanced sensor and atherectomy technologies. By combining these technologies with our expertise in wires and components, we believe the manipulability of these products will improve dramatically," said Masahiko Miyata, president and CEO, Asahi Intecc. "Through our collaboration with Boston Scientific, we are confident that we will be able to help improve outcomes for patients."

Asahi Intecc specializes in wire drawing, wire forming, torque transmission and coating processes for percutaneous transluminal coronary angiography (PTCA) guidewires.

Boston Scientific anticipates commercializing both specialty wires in 2015.

For more information: www.bostonscientific.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init